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Abstract  
Objective: To compare number of days lost to illness or accessing healthcare for HIV-positive and 
HIV-negative individuals working in the informal and formal sectors in South Africa and Zambia.  
Design: As part of the HPTN 071 (PopART) study, data on adults aged 18-44 years were gathered 
between in cross-sectional surveys of random general population samples in 21 communities in 
Zambia and South Africa. Data on the number of productive days lost in the last 3 months, laboratory-
confirmed HIV status, labour force status, age, ethnicity, education, and recreational drug use was 
collected.  
Methods: Differences in productive days lost between HIV-negative and HIV-positive individuals 
(“excess productive days lost”) were estimated with negative binomial models, and results 
disaggregated for HIV-positive individuals after various durations on Anti-retroviral treatment (ART).  
Results: From samples of 19,330 respondents in Zambia and 18,004 respondents in South Africa, 
HIV-positive individuals lost more productive days to illness than HIV-negative individuals in both 
countries. HIV-positive individuals in Zambia lost 0·74 excess productive days (95%CI: 0·48-1·01; 
p<0·001) to illness over a three-month period. HIV-positive in South Africa lost 0·13 excess days 
(95%CI: 0·04-0·23; p=0·007). In Zambia, those on ART for less than one year lost most days, and 
those not on ART lost fewest days. In South Africa, results disaggregated by treatment duration were 
not statistically significant.  
Conclusions: There is a loss of work and home productivity associated with HIV, but it is lower than 
existing estimates for HIV-positive formal sector workers. The findings support policy makers in 
building an accurate investment case for HIV interventions. 
Keywords: HIV/AIDS, labour productivity, sickness days, absenteeism, informal sector, economics 
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Introduction 
The majority of people living with HIV (PLWH) are in their most productive phase of life. 
Worldwide, 78% of individuals living with HIV are between the ages of 15 and 49 [1], and 
most of them are either working, studying, or engaged in housework and caring for children 
or the elderly. Prior to the expansion of anti-retroviral therapy (ART) in low-income 
countries, health status and productivity of HIV-positive individuals declined as HIV 
infection progressed to AIDS and premature death. This had serious consequences for the 
social and economic situation of PLWH and their households. The expanded availability of 
ART rapidly restored health and physical functioning [2] and extended life expectancy [3, 4], 
thereby restoring and maintaining worker productivity and the well-being of households [5, 
6].  
The success of ART in safe-guarding the livelihoods of PLWH and their households plays an 
important role in motivating the global response to the epidemic [7]. The ambitious 2015 
UNAIDS Fast Track Targets for improved access to treatment are partly motivated by 
modelling predictions of large economic gains due to improved labour productivity [8, 9]. 
These predictions are based on evidence of how the productivity of workers in formal 
employment recovers before and after ART initiation. It is unclear, however, whether the 
predictions apply to the wider HIV-infected population. In low- and middle-income countries 
(LMICs), the majority of individuals are not formally employed; in sub-Saharan Africa, 
informal sector workers make up 88% of the labour force [10]. They often have precarious 
informal employment without contracts, no paid sick leave, lower wages and longer working 
hours, and therefore face different incentives with respect to absenteeism than formal sector 
workers. Informal workers may simply be unable to afford taking days off work. Individuals 
engaged in housework and those studying make valuable contributions to households, 
communities and the economy, but have also been excluded from most previous analyses.  
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We conducted this study in two of the most HIV/AIDS affected countries globally; South 
Africa and Zambia, to compare the productive days lost (PDLs) by PLWH with those lost by 
HIV-negative individuals. It is the first analysis of the association between PDLs and 
HIV/AIDS in a random sample of adults. It includes individuals in formal and informal 
employment, and those not in the labour force. Most previous studies that estimated excess 
PDLs analysed employees at one or a few companies, including tea plantations in Kenya [11-
14], mining companies in South Africa and Botswana [5, 15], and a public sector 
organization in Zambia [16] (see A1 for a literature review, 
http://links.lww.com/QAD/B450). Studies were mostly small in scale, with a median sample 
size of 2051 (min: 87, max: 7666), which included a median number of HIV-positive of 237 
(min: 11, max: 1703). Our study provides a rare insight into the productivity of PLWH at all 
stages of engagement with HIV care, including PLWH before diagnosis. Only three previous 
studies [15, 17, 18] analysed PLWH at all stages of disease, while four [5, 12-14] analysed 
HIV-positive employees before and after initiation of ART, and two [11, 16] focused 
exclusively on PLWH shortly before death. Our study design enabled adjustment for 
confounders that were collected for HIV-positive and HIV-negative in the same way. HIV 
status was determined from blood samples taken during the survey and confirmed with 
laboratory testing. All previous studies except three [15, 17, 18] benchmarked HIV-positive 
individuals against employees with unknown HIV status, therefore the comparison groups 
used by previous studies may have been distorted by an unknown number of HIV-positive 
individuals. 
Methods 
Study population and data 
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The survey was conducted as the baseline of the on-going HPTN 071 (PopART) cluster-
randomised trial measuring the effect of a combination prevention intervention on population 
level HIV-incidence [19]. HPTN 071 was implemented in 21 communities: 12 in Zambia 
covering four provinces and six districts, and 9 in South Africa in the Cape Metro and Cape 
Winelands districts of the Western Cape Province (A2, http://links.lww.com/QAD/B450). 
The study population is a cross-sectional random sample of adults between 18-44 years, 
resident within a household in the communities enrolled in the HPTN 071 (PopART) trial. 
Study participants consented to complete a research questionnaire, and to donate a venous 
blood sample annually, which was tested for HIV using a 4th generation assay (A3, 
http://links.lww.com/QAD/B450). The data used in this paper was gathered between 
November 2013 and March 2015.   
From each randomly selected household, one adult was randomly selected for participation in 
the survey (A4, http://links.lww.com/QAD/B450). The survey gathered information on HIV 
testing, socio-demographics, health, economic, and behavioural variables. PDLs were 
measured as responses to the question “In the last 3 months, how many days have you been 
prevented from doing your usual work due to your own sickness or seeking healthcare?”. We 
followed convention in the labour economics literature and defined ‘in the labour force’ (ILF) 
as those self-reporting being currently employed, self-employed, unemployed (looking for 
work or waiting to start new work), or waiting to continue agricultural work [20]. ‘Not in the 
labour force’ (NILF) included homemakers, students, retirees and others not looking for 
work. Those reporting being permanently sick or disabled were excluded from the analysis. If 
respondents self-reported being HIV-positive, information was gathered on whether they 
were in HIV care, and whether and for how long they had been on ART.  
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A full ethics review of the trial protocol (DOI https://doi.org/10.1186/1745-6215-15-57) was 
done by the ethics committees of the University of Zambia, University of Stellenbosch, and 
the London School of Hygiene & Tropical Medicine. 
Statistical analysis 
We used multivariate negative binomial regression (NegBin) models with a quadratic 
variance function to evaluate the effect of HIV status on PDL. The NegBin model is 
appropriate because the dependent variable PDL is over-dispersed [21] with a variance 
greater than its mean (A5, http://links.lww.com/QAD/B450). We used STATA (version 14) 
and its nbreg routine for estimation, and countfit routine for evaluating model fit of the 
NegBin compared to a standard Poisson model [22, 23]. 
Results are presented as both marginal effects and predicted values evaluated at the means of 
all other covariates. A positive marginal effect represents the additional or “excess PDLs” 
that PLWH lose due to illness and/or accessing health care over three months when compared 
to HIV-negative individuals. The predicted value represents the total PDLs for specified 
subgroups of the sample, measured in number of days over three months. Two model 
specifications per country were estimated. In the first specification (models 1a and 2a), HIV 
status was classified as a binary indicator representing laboratory-confirmed HIV-positive 
and HIV-negative individuals. In the second specification (models 1b and 2b), four categories 
of HIV-positive status were defined, with HIV-negative individuals as the base case: HIV-
positive and not on ART, HIV-positive on ART less than 1 year, HIV-positive on ART 1-2 
years, and HIV-positive on ART 3 or more years. The models included as adjustment 
variables: age, gender, education, ethnic group, use of recreational drugs, and labour force 
participation status. All models also included dummy variables for each community to 
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capture unobservable differences across communities. Models were estimated separately for 
Zambia and South Africa.  
Results 
The full survey sample included responses from 19,750 (83%) of 23,676 randomly selected 
individuals in Zambia and 18,941 (88%) of 21568 randomly selected individuals in South 
Africa (table 1). Laboratory confirmed HIV status was available for 19,330 (98%) 
participants in Zambia and 18,004 (95%) in South Africa; of whom 4,128 (21%) and 4,012 
(22%) were HIV-positive, respectively. In both countries, the majority of PLWH reported not 
being on ART. Amongst those HIV-positive and on ART, the largest proportion were on 
ART for 3 or more years, followed by on ART for less than 1 year. The mean number of 
PDLs reported for the three-month period before the interview was 1.3 days (SD: 6.11 days) 
for participants from Zambia and 0.31 days (SD: 3.0 days) for participants from South Africa. 
Among PLWH in Zambia, 13% reported having more than 3 PDLs in the past three-months, 
compared to 7% of HIV-negative individuals. There was no difference between the two 
groups in South Africa (2%). In both countries, average PDLs were higher for HIV-positive 
(Zambia: 2.17, SD: 8.31; South Africa: 0.48, SD: 4.29) than HIV-negative (Zambia: 1.03, 
SD: 5.25; South Africa: 0.26, SD: 2.59) individuals. The majority of respondents were female 
and had completed secondary education. Labour force participation was higher in South 
Africa than in Zambia.  
In Zambia, PLWH lost a total of 1.70 days over three months on average (CI: 1.44-1.95, table 
3); these were 0.74 “excess PDLs”, i.e. 0.74 more days (CI: 0.48-1.01; p<0.001, model 1a, 
table 2) than HIV-negative individuals, who lost a total of 0.95 (CI: 0.88-1.02) days (table 3). 
Compared to HIV-negative individuals, being on ART for less than 1 year was associated 
with the largest number of excess PDLs (1.24; 95%CI: 0.34-2.14; p=0.007, model 1b), 
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followed by being on ART between 1 to 2 years (1.08; 95%CI: 0.06-2.11; p=0.038, model 
1b), being on ART for 3 or more years (0.79; 95%CI: 0.16-1.41; p=0.014,model 1b) and 
being HIV-positive but not on ART (0.61; CI: 0.30-0.92; p<0.001, model 1b). In South 
Africa, PLWH lost a total of 0.31 days over three months on average (95%CI: 0.22-0.40), an 
excess of 0.13 days (95%CI: 0.04-0.23; p=0.007, model 2a) compared to HIV-negative 
individuals who lost 0.18 days in total (95%CI: 0.15-0.20). We found no significant 
differences when HIV-status was disaggregated by duration on ART for individuals in the 
South African communities.  
When examining differences in total predicted values for both countries, PDLs were much 
lower in South Africa than in Zambia for nearly all subgroups (table 3). Of the four groups 
formed based on HIV and labour force status, HIV-positive ILF had highest PDLs at 1.88 
(95%CI: 1.57-2.19) and 0.32 (95%CI: 0.23-0.41) in Zambia and South Africa, respectively, 
followed by HIV-positive NILF at 1.54 (95%CI: 1.28—1.80) and 0.26 (95%CI: 0.14-0.37), 
HIV-negative ILF at 1.05 (95%CI: 0.94-1.17) and 0.18 (95%CI: 0.15-0.21), and HIV-
negative NILF with lowest PDLs at 0.86 (95%CI: 0.78-0.95) and 0.15 (95%CI: 0.10-0.20). 
Predicted PDLs increased with age. Among HIV-positive individuals, 35-44 year olds who 
had been on ART for less than one year had highest PDLs at 3.38 days (95%CI: 1.94-4.81) in 
Zambia, and 2.24 days (95%CI: 0.19-4.28) in South Africa, while under 25 year olds who 
were not on ART had lowest PDLs at 1.24 days (95%CI: 0.97-1.51) in Zambia, and 0.16 days 
(95%CI: 0.09-0.23) in South Africa.  
There was no substantial gender difference in predicted PDLs among HIV-positive and HIV-
negative individuals in both countries. HIV-negative and HIV-positive individuals across all 
categories who had completed secondary school had lower PDLs than those with primary 
school and higher education in Zambia. In South Africa, those with higher education had 
fewest PDLs, followed by those with secondary education and those with primary education. 
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Predicted PDLs also differed across regions in Zambia, but there was little variation across 
regions in South Africa. Likelihood ratio tests for comparison with the Poisson model 
rejected the null of no over-dispersion (table 2), confirming that NegBin provided a better fit 
(A6, http://links.lww.com/QAD/B450). 
Discussion 
This is the first study of productive days lost to illness or accessing health care among HIV-
positive and HIV-negative individuals in a random sample of adults in sub-Saharan Africa. It 
offers a rare insight into PDLs for the large majority of the population that is informally 
employed, self-employed, unemployed or not part of the labour force. The study further 
provides estimates of the PDLs of PLWH at different stages of engagement with HIV care, 
including those not on treatment, and those who were unaware of their status (44% in Zambia 
and 53% in South Africa) [2]. We undertook a direct comparison of PDLs between HIV-
positive and HIV-negative individuals based on laboratory-confirmed HIV status. HIV-
negative individuals provided an important benchmark that allowed us to analyse the 
association between HIV and PDLs, which is crucial information in countries with competing 
risks that impede productivity, most notably other diseases. We analysed PDLs which were 
lost to both sickness and accessing health care. Travel and waiting times at facilities have 
been identified as important barriers to accessing and remaining in HIV care [24]. We 
performed analyses separately for Zambia and South Africa because of substantial 
differences in labour markets, social security and health care systems. 
In Zambia, 21% of the sample were HIV-positive and had 0.74 more PDLs than HIV-
negative individuals over three months, while in South Africa, the 22% PLWHs had only 
0.13 more PDLs. Our estimates are markedly lower than those from previous studies [5, 11-
17]; the median excess PDLs across eight previous studies was 5.1 days over three months, 
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with high standard deviation of 9.55 and estimates ranging between zero to over 33 excess 
PDLs for HIV-positive workers in their final year of life. Previous studies analysed PLWH in 
formal employment who were not representative of the population of PLWH, which may 
explain some of the divergence. Most formal sector workers enjoy statutory paid sick leave 
and have therefore lower opportunity costs of work absenteeism. Most respondents in our 
sample were informal sector workers, or unemployed workers with informal jobs and less 
able to afford a day of lost pay. This may explain why our estimates are lower than those of 
previous studies. Moreover, our disaggregated results for Zambia indicate that the two HIV-
positive fractions with the lowest excess PDLs, i.e. those not on ART and those on ART for 
three years or more together, make up 76% of the HIV-positive population. It seems 
reasonable that these groups lose fewer days than those more recently started on ART, 
because the former are in the earlier stages of the disease (and therefore not yet on ART), and 
the latter are virally suppressed because they have been on ART long-term. Our comparison 
of community-level variations in excess PDLs showed significant differences within Zambia, 
but less so across communities in South Africa. These differences may be driven by a range 
of unobservable factors that are not captured in the model, including variations in economic 
conditions across regions, health system differences and social norms. The larger variations 
observed in Zambia are most likely because the study communities are spread across the 
country, reflecting the heterogeneity across regions, whereas in South Africa, the 
communities are all located in the Western Cape Province, and thus more likely to be similar 
in unobservable characteristics.   
Five of nine previous studies were conducted before 2010 when ART was less accessible, or 
they focused on the (nowadays) small and non-representative subgroup of PLWH in their 
final year of life, or with AIDS [11, 15-17], and it is likely that they had higher PDLs than the 
population of PLWH today. Longitudinal studies among infected agricultural and mining 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
workers are consistent with our findings. They have demonstrated a V-shaped pattern for 
labour force participation and productivity over the course of HIV disease, declining sharply 
as symptoms worsen in the months before ART initiation and rebounding within a few 
months to levels close to those experienced prior to becoming symptomatic [12, 13, 25-27]. 
Across all CD4 cell count ranges except <50 μL, PLWH receiving ART are less absent than 
those not receiving treatment [28].  
Estimates of PDL are higher for Zambia than for South Africa. It is possible that PDLs are 
affected by the time lost accessing health care, rather than inability to work due to sickness. 
Since guidelines for both countries stipulate quarterly clinic visits for PLWH, the differences 
are likely explained by variations in travel and clinic waiting timings between the two 
countries. However, because the proportion of PLWH not on ART is only slightly higher in 
South Africa, it is unlikely that barriers to access can explain all differences. We could not 
find comparable empirical estimates of waiting times for the two countries; an evidence gap 
that requires further research. If PDLs were mainly explained by inefficiencies in accessing 
care, then they could possibly be reduced by supply-side interventions. Differentiated models 
of care policies, such as community pick-up points and adherence clubs, are being rolled out 
in both countries. They aim to shorten the time required to pick up drugs, and promise to 
remove or lower existing access barriers with possibly positive effects for PDLs [29].   
This study has limitations. First, PDLs are based on self-reports and did not account for 
reduced productivity on working days, possibly underestimating productivity losses. Most 
previous studies have used employment records, but these are not available for informal 
sector workers and individuals not in the labour force. It is also difficult to measure reduced 
productivity while working. Second, we had no information on individuals’ clinical disease 
stage, and so stratified PDLs for PLWH by self-reported time on ART, which could have 
been affected by recall bias. This would not affect our overall estimates, but potentially those 
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by treatment stage. However, mean CD4 cell count at ART initiation has remained at about 
152 per μL in the past decade in sub-Saharan Africa [30]. Our results for Zambia suggest that 
after 2 years on ART, PDLs recover almost to those of individuals in earlier disease stages, a 
finding corroborated by previous studies on HIV-positive workers [12, 13, 25-27]. We also 
had to rely on self-reports of ART initiation amongst those self-reporting being HIV-positive, 
which may have resulted in some over-classification of individuals into the “not being on 
ART category”. Third, we could not control for all covariates that may affect PDLs, for 
example, the presence of other working age individuals in the household, something not 
assessed in our sample. Moreover, women are overrepresented in our sample, which may bias 
our findings. However, we control for gender in all models and the predicted PDLs for men 
and women are very similar in Zambia, and not statistically different in South Africa. Finally, 
our data comes from communities in urban and peri-urban areas with comparably high HIV 
prevalence and are therefore not necessarily representative of other communities in the two 
countries.  
We have calculated the days of work and home productivity lost to illness of all individuals 
irrespective of whether they were in the labour force, overcoming ethical issues that arise 
when comparing the benefits of interventions between individuals who are working and those 
who are not, even if they make positive contributions to society. These estimates could be 
used to calculate the opportunity costs of HIV in monetary terms, for example, by 
multiplying the estimates with GDP per capita or minimum wage rates. However, micro 
estimates of productivity such as ours are incorrect estimates of future financial gains 
resulting from prevention or treatment interventions; they may under- or overestimate the 
aggregate productivity benefits from improved health [31]. Projection of the future macro-
economic impact requires more complex general equilibrium modelling which considers 
additional factors, such as the degree to which infections are concentrated in hard-to-replace 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
skilled workers, levels of unemployment, the impact of interventions on life expectancy, 
education, migration, and changes in public and private savings or investments [7, 31]. 
Our results provide estimates of the burden of the HIV-epidemic resulting from lost work and 
home productivity in Zambia and South Africa. These will be a crucial input for modelling 
studies that aim to calculate the number of days lost to sickness that could be averted through 
programs of enhanced HIV prevention and treatment, and to comprehensively assess the 
economic benefit of such programs.  We generated predictions of PDLs in various subgroups 
so that our findings are useful for a wide range of future studies. UNAIDS policies directed at 
achieving the ambitious 90-90-90 targets [32], are partly motivated by estimates of improved 
work productivity generated by simulation studies [8, 9]. Our findings help to assess the 
validity of the assumptions on which these studies were based. For example, our results 
showed that HIV-negative workers do not have a null absenteeism rate (previous studies 
assumed that they do), and that labour productivity of persons on ART for 3 or more years is 
very similar to asymptomatic HIV-infected adults (previous studies assumed that it is 
substantially less) [8, 9]. 
As part of the United Nations’ Sustainable Development Goals, the world has pledged to end 
the AIDS epidemic as a public health threat by 2030. To reach this ambitious goal, UNAIDS 
estimates that domestic and international investments in HIV programs in LMICs need to 
increase by about one third, from an estimated US$ 19.1 billion in 2016 to US$ 26.2 billion 
until 2020 [33]. This represents a substantial allocation of resources that might otherwise be 
used for alternative worthwhile projects. At country level, HIV interventions must compete 
against public investments into other interventions in the areas of health, education, 
infrastructure, housing, or agriculture. The benefits of these investments are commonly 
assessed on basis of their economic returns. It is difficult for policy makers to compare the 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
benefits of the large investments needed to end the epidemic when their returns are only 
measured in terms of health outcomes, even if those are substantial. The findings from this 
study form an important contribution towards building a comprehensive and accurate 
investment case for HIV prevention and treatment interventions based upon their monetary 
benefits.  
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Table 1: Demographic and socio-economic characteristics of a random sample of adults 
18-44 years of age in 21 communities in Zambia and South Africa 
  Zambia South Africa 
  N=19750  N=18941  
Productive days lost (PDLs) in 
the last 3 months 
1.3 6.11 0.31 3 
PDLs, HIV-positive 2.17 8.31 0.48 4.29 
PDLs, HIV-negative 1.03 5.25 0.26 2.59 
PDLS>3 days, HIV-positive 526/3,952 13% 87/3,821 2% 
PDLS>3 days, HIV-negative 1,069/14,496  7% 208/12,862 2% 
Age under 25 years 8,894/19,730 45% 6,355/18,610 34% 
Age 25 to 34 years 7,193/19,730 37% 7,597/18,610 41% 
Age 35 to 44 years 3,643/19,730 18% 4,658/18,610 25% 
Sex     
Male 5,428/19,733 28% 5,816/18,612 31% 
Female 14,305/19,733 72% 12,796/18,612 69% 
Labour force participation      
In the labour force 8,785/18,623 47% 15,133/18,400 82% 
Not in the labour force 9,799/18,623 53% 3,112/18,400 17% 
Unable to work (permanently 
sick or injured) 
39/18,623 0% 155/18,400 1% 
Ethnic group      
 Bemba 5,827/19,750 30% Xhosa 
12,048/18,941 
64% 
 Tonga 2,453/19,750 12% Multiracial 
4,803/18,941 
25% 
 Lozi 1,547/19,750 8% Afrikaans 
526/18,941 
3% 
 Chewa 1,404/19,750 7% Other@ 
1,564/18,941 
8% 
 Other@ 8,519/19,750 43%   
Education Level      
School education less than grade 
8 (primary school) 
5,544/19,668 28% 1,472/18,466 8% 
School education between grades 
8 and 12 (secondary school) 
12,808/19,668 65% 15,947/18,466 86% 
College, university, or other 
higher education 
1,316/19,668 7% 1,047/18,466 6% 
Use recreational drugs  480/19,629 2% 689/18,432 4% 
HIV-status      
HIV-negative 15,202/19,330 79% 13,992/18,004  78% 
HIV-positive 4,128/19,330 21% 4,012/18,004 22% 
HIV-positive not on ART*~ 2,446/4,128 59% 2,592/4,012 65% 
HIV-positive on ART <1 year* 509/4,128 12% 351/4,012 9% 
HIV-positive on ART 1-2 years* 347/4,128 8% 268/4,012 7% 
HIV-positive on ART 3 or more 
years* 
714/4,128 17% 574/4,012 14% 
Unknown ART status*ⱡ 112/4,128 3% 227/4,012 6% 
 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Notes: Data are mean (SD), n (%), or n/N (%). @All other ethnic groups varied between 
0.03% and 6.69%.  *ART status at the start of the 3-month recall period of PDLs; numbers 
based on responses by those self-reporting being HIV-positive.  ~Includes respondents with 
lab confirmed HIV-positive status who did not self-report being HIV-positive.  ⱡ Includes 
respondents with missing self-reported ART status. 
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Table 2: Multivariable analysis of factors associated with productive days lost 
 Zambia South Africa 
 Model 1a Model 1b Model 2a Model 2b 
HIV-negative (base) -- -- -- -- 
               
HIV-positive 0·74***  0·13***  
  [0·48,1·01] 
p<0·001 
 [0·04,0·23] 
p=0·007 
 
HIV-positive not on 
ART 
 0·61***  0·03 
            [0·30,0·92] 
p<0·001 
 [-0·05,0·11] 
p=0·416 
HIV-positive on ART 
< 1 yr 
 1·24***  1·41 
            [0·34,2·14] 
p=0·007 
 [-0·004,2·82] 
p=0·051 
HIV-positive on ART 
1-2yrs 
 1·08**  0·18 
            [0·06,2·11] 
p=0·038 
 [-0·19,0·54] 
p=0·341 
HIV-positive on ART 
3 or more yrs 
 0·79**  0 
            [0·16,1·41] 
p=0·014 
 [-0·13,0·14] 
p=0·961 
In the labour force 
(base) 
-- -- -- -- 
               
Not in the labour force -0·05 -0·04 0 0·001 
           [-0·21,0·11] 
p=0·571 
[-0·20,0·12] 
p=0·592 
[-0·08,0·08] 
p=0·989 
[-0·07,0·07] 
p=0·982 
Under 25 years (base)  -- -- -- -- 
               
25 to 34   years 0·25*** 0·24*** 0·06** 0·05 
           [0·08,0·41] 
p=0·003 
[0·08,0·40] 
p=0·004 
[0·01,0·12] 
p=0·031 
[-0·01,0·10] 
p=0·082 
35 to 44  years 0·73*** 0·72*** 0·11*** 0·11*** 
           [0·44,1·02] 
p<0·001 
[0·43,1·02] 
p<0·001 
[0·03,0·19] 
p=0·006 
[0·03,0·19] 
p=0·006 
Female (base)    -- -- -- -- 
               
Male       -0·05 -0·04 -0·08*** -0·10*** 
           [-0·22,0·12] 
p=0·593 
[-0·21,0·13] 
p=0·626 
[-0·14,-0·03] 
p=0·002 
[-0·15,-0·05] 
p=<0·000 
Bemba (base Zambia) 
/ Xhosa (base South 
Africa)     
-- -- -- -- 
               
Tonga (Zambia) / 0·13 0·14 0·01 0·01 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Multiracial (South 
Africa)     
           [-0·16,0·41] 
p=0·383 
[-0·15,0·42] 
p=0·353 
[-0·09,0·11] 
p=0·841 
[-0·08,0·10] 
p=0·850 
Lozi (Zambia) / 
Afrikaans (South 
Africa)   
0·15 0·14 0·87 0·81 
           [-0·20,0·49] 
p=0·403 
[-0·20,0·48] 
p=0·418 
[-0·84,2·59] 
p=0·319 
[-0·77,2·40] 
p=0·314 
Chewa (Zambia)      0·22 0·23   
           [-0·12,0·57] 
p=0·209 
[-0·12,0·57] 
p=0·201 
  
Other      0·03 0·03 -0·06 -0·07** 
           [-0·14,0·20] 
p=0·728 
[-0·14,0·21] 
p=0·711 
[-0·14,0·02] 
p=0·164 
[-0·14,-0·00] 
p=0·045 
School education less 
than grade 8 (primary 
school, base) 
    
               
School education 
between grades 8 and 
12 (secondary school) 
-0·23** -0·23** -0·13 -0·04 
           [-0·43,-0·03] 
p=0·026 
[-0·43,-0·03] 
p=0·025 
[-0·29,0·03] 
p=0·228 
[-0·16,0·08] 
p=0·513 
College, university, or 
other higher education 
-0·2 -0·19 -0·14 -0·05 
           [-0·54,0·14] 
p=0·260 
[-0·53,0·15] 
p=0·265 
[-0·33,0·04] 
p=0·135 
[-0·20,0·10] 
p=0·505 
Does not use 
recreational drugs 
    
               
Uses recreational 
drugs 
0·54 0·53 0·14 0·16 
           [-0·16,1·24] 
p=0·131 
[-0·17,1·22] 
p=0·137 
[-0·09,0·36] 
p=0·235 
[-0·07,0·40] 
p=0·169 
Community fixed 
effects 
Yes Yes Yes Yes 
N 17397 17324 16219 16086 
Likelihood ratio test ሺࡴ࢕: ࢻ ൌ ૙ሻ     ࣑૛ 86000 85000 26000 26000 
Prob >= ࣑૛ 0·0000 0·0000 0·0000 0·0000 
Note: *** and ** denote 99% and 95% statistical confidence levels, respectively; Presented are 
marginal effects evaluated at the means of all other covariates; Data are change in mean PDLs (95% 
CI), unless otherwise stated. For all factor variables, each category is compared with the base 
category. 
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Table 3: Predicted productive days lost over 3 months, by HIV-status and for various subgroups 
  Zambia South Africa 
Subgroups HIV-
negative@ 
HIV-
positive* 
HIV-
positive not 
on ART@ 
HIV-
positive on 
ART < 1 
yr@ 
HIV-
positive 1-2 
yrs@ 
HIV-
positive on 
ART 3 yrs 
+@ 
HIV-
negative
@ 
HIV-
positive* 
HIV-
positive not 
on ART@ 
HIV-
positive on 
ART < 1 
yr@ 
HIV-
positive 1-
2 yrs@ 
HIV-
positive on 
ART 3 yrs 
+@ 
All 0·95 
[0·876,1·0
23] 
1·70 
[1·441,1·
952] 
1·56 
[1·261,1·858
] 
2·19 
[1·296,3·084
] 
2·03 
[1·011,3·056
] 
1·74 
[1·119,2·357
] 
0·18 
[0·149,0·
201] 
0·31 
[0·220,0·400
] 
0·21 
[0·136,0·28
0] 
1·58 
[0·172,2·997
] 
0·35 
[-
0·011,0·71
4] 
0·18 
[0·050,0·30
7] 
Under 25 
years 
0·75 
[0·675,0·8
34] 
1·34 
[1·093,1·
590] 
1·24 
[0·972,1·506
] 
1·74 
[1·006,2·475
] 
1·62 
[0·780,2·453
] 
1·38 
[0·860,1·902
] 
0·14 
[0·105,0·
168] 
0·23 
[0·143,0·319
] 
0·16 
[0·095,0·22
7] 
1·23 
[0·083,2·380
] 
0·27 
[-
0·019,0·56
6] 
0·14 
[0·032,0·24
6] 
25 - 34 years 1·01 
[0·885,1·1
30] 
1·80 
[1·500,2·
109] 
1·65 
[1·312,1·996
] 
2·32 
[1·359,3·287
] 
2·16 
[1·069,3·246
] 
1·84 
[1·169,2·518
] 
0·18 
[0·136,0·
215] 
0·32 
[0·220,0·424
] 
0·21 
[0·130,0·28
7] 
1·59 
[0·169,3·008
] 
0·35 
[-
0·008,0·71
3] 
0·18 
[0·046,0·31
1] 
35-44 years 1·46 
[1·212,1·7
17] 
2·62 
[2·124,3·
122] 
2·40 
[1·846,2·963
] 
3·38 
[1·941,4·812
] 
3·14 
[1·520,4·751
] 
2·68 
[1·717,3·641
] 
0·25 
[0·177,0·
317] 
0·43 
[0·282,0·587
] 
0·29 
[0·173,0·41
3] 
2·24 
[0·195,4·282
] 
0·50 
[-
0·028,1·02
3] 
0·25 
[0·072,0·43
2] 
Female 0·95 
[0·864,1·0
35] 
1·70 
[1·438,1·
957] 
1·56 
[1·257,1·862
] 
2·19 
[1·293,3·086
] 
2·03 
[1·014,3·052
] 
1·74 
[1·119,2·355
] 
0·21 
[0·169,0·
242] 
0·35 
[0·246,0·458
] 
0·24 
[0·158,0·33
0] 
1·86 
[0·183,3·541
] 
0·41 
[-
0·012,0·83
9] 
0·21 
[0·060,0·36
0] 
Male 0·95 
[0·825,1·0
76] 
1·69 
[1·363,2·
024] 
1·56 
[1·209,1·912
] 
2·19 
[1·260,3·124
] 
2·04 
[0·971,3·099
] 
1·74 
[1·077,2·401
] 
0·12 
[0·092,0·
153] 
0·23 
[0·148,0·317
] 
0·15 
[0·085,0·20
5] 
1·11 
[0·108,2·107
] 
0·25 
[-
0·016,0·50
8] 
0·12 
[0·028,0·22
1] 
School 
education < 
1·07 
[0·926,1·2
1·92 
[1·577,2·
1·76 
[1·384,2·145
2·48 
[1·440,3·517
2·30 
[1·120,3·483
1·97 
[1·249,2·684
0·26 
[0·136,0·
0·60 
[0·282,0·927
0·31 
[0·123,0·49
2·36 
[0·154,4·561
0·52 
[-
0·27 
[0·040,0·49
Copyright © 2019 W
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  Zambia South Africa 
Subgroups HIV-
negative@ 
HIV-
positive* 
HIV-
positive not 
on ART@ 
HIV-
positive on 
ART < 1 
yr@ 
HIV-
positive 1-2 
yrs@ 
HIV-
positive on 
ART 3 yrs 
+@ 
HIV-
negative
@ 
HIV-
positive* 
HIV-
positive not 
on ART@ 
HIV-
positive on 
ART < 1 
yr@ 
HIV-
positive 1-
2 yrs@ 
HIV-
positive on 
ART 3 yrs 
+@ 
grade 8 
(primary) 
23] 262] ] ] ] ] 385] ] 5] ] 0·073,1·12
0] 
1] 
School 
education 
grades 8 - 12 
(secondary) 
0·89 
[0·805,0·9
67] 
1·58 
[1·326,1·
839] 
1·45 
[1·165,1·745
] 
2·04 
[1·199,2·887
] 
1·90 
[0·939,2·855
] 
1·62 
[1·033,2·209
] 
0·17 
[0·146,0·
202] 
0·30 
[0·212,0·389
] 
0·21 
[0·135,0·27
7] 
1·57 
[0·159,2·986
] 
0·35 
[-
0·010,0·70
8] 
0·18 
[0·049,0·30
5] 
College, 
university, or 
other higher 
education 
1·10 
[0·816,1·3
90] 
1·97 
[1·383,2·
554] 
 
1·81 
[1·231,2·391
] 
2·54 
[1·332,3·756
] 
2·36 
[1·016,3·708
] 
2·02 
[1·126,2·910
] 
0·11 
[0·049,0·
181] 
0·20 
[0·068,0·328
] 
0·14 
[0·045,0·22
7] 
1·04 [-
0·066,2·143]
0·23 
[-
0·049,0·51
0] 
0·12 
[0·008,0·22
6] 
In the labour 
force 
1·05 
[0·941,1·1
65] 
1·88 
[1·572,2·
193] 
1·73 
[1·378,2·080
] 
2·43 
[1·430,3·425
] 
2·25 
[1·104,3·405
] 
1·93 
[1·229,2·623
] 
0·18 
[0·151,0·
210] 
0·32 
[0·228,0·414
] 
0·21 
[0·140,0·28
9] 
1·64 
[0·181,3·091
] 
0·36 
[-
0·011,0·73
8] 
0·18 
[0·052,0·31
6] 
Not in the 
labour force 
0·86 
[0·776,0·9
51] 
1·54 
[1·285,1·
798] 
1·42 
[1·130,1·707
] 
1·99 
[1·162,2·822
] 
1·85 
[0·916,2·783
] 
1·58 
[1·005,2·155
] 
0·15 
[0·100,0·
197] 
0·26 
[0·140,0·372
] 
0·18 
[0·091,0·26
1] 
1·34 
[0·053,2·634
] 
0·30 
[-
0·023,0·62
0] 
0·15 
[0·029,0·27
3] 
Bemba 
(Zambia) / 
Xhosa (South 
Africa) 
0·77 
[0·673,0·8
75] 
1·38 
[1·122,1·
648] 
1·27 
[0·986,1·556
] 
1·78 
[1·032,2·537
] 
1·66 
[0·803,2·511
] 
1·42 
[0·884,1·948
] 
0·16 
[0·128,0·
187] 
0·28 
[0·199,0·359
] 
0·19 
[0·122,0·25
1] 
1·43 
[0·155,2·696
] 
0·32 
[-
0·008,0·64
1] 
0·16 
[0·045,0·27
6] 
Tonga 
(Zambia) / 
Multi-racial 
(South 
Africa) 
1·25 
[1·008,1·4
96] 
2·22 
[1·694,2·
750] 
2·06 
[1·511,2·600
] 
2·89 
[1·588,4·186
] 
2·68 
[1·231,4·131
] 
2·29 
[1·381,3·199
] 
0·28 
[0·207,0·
344] 
0·48 
[0·282,0·676
] 
0·33 
[0·183,0·47
1] 
2·50 
[0·157,4·834
] 
0·55 
[-
0·040,1·14
8] 
0·28 
[0·062,0·50
0] 
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  Zambia South Africa 
Subgroups HIV-
negative@ 
HIV-
positive* 
HIV-
positive not 
on ART@ 
HIV-
positive on 
ART < 1 
yr@ 
HIV-
positive 1-2 
yrs@ 
HIV-
positive on 
ART 3 yrs 
+@ 
HIV-
negative
@ 
HIV-
positive* 
HIV-
positive not 
on ART@ 
HIV-
positive on 
ART < 1 
yr@ 
HIV-
positive 1-
2 yrs@ 
HIV-
positive on 
ART 3 yrs 
+@ 
Lozi 
(Zambia) / 
Afrikaans 
(South 
Africa) 
1·20 
[0·901,1·5
03] 
2·16 
[1·581,2·
744] 
1·97 
[1·383,2·564
] 
2·77 
[1·491,4·052
] 
2·57 
[1·166,3·981
] 
2·20 
[1·279,3·118
] 
0·72 [-
0·383,1·8
23] 
1·26 [-
0·719,3·240]
0·85 [-
0·475,2·18
1] 
6·51 [-
4·959,17·98
4] 
1·45 
[-
1·212,4·10
4] 
0·73 
[-
0·502,1·96
8] 
Chewa 
(Zambia) 
1·26 
[0·930,1·5
80] 
2·23 
[1·587,2·
882] 
2·06 
[1·418,2·703
] 
2·89 
[1·509,4·280
] 
2·69 
[1·174,4·202
] 
2·30 
[1·301,3·292
] 
      
Other 0·92 
[0·820,1·0
26] 
1·65 
[1·371,1·
923] 
1·52 
[1·207,1·824
] 
2·13 
[1·243,3·015
] 
1·98 
[0·975,2·979
] 
1·69 
[1·072,2·305
] 
0·07 
[0·032,0·
112] 
0·14 
[0·055,0·216
] 
0·09 
[0·032,0·14
0] 
0·65 [-
0·011,1·320]
0·15 
[-
0·027,0·31
8] 
0·07 
[0·009,0·13
9] 
Note: Confidence intervals of the mean prediction from a hypothesis test of significant difference from zero; PDLs for aggregate categories not 
displayed in the table can be approximated by the weighted averages of PDLs across the respective disaggregated categories. For example, PDLs 
for the 1570 (509+347+714) individuals on ART in Zambia can be calculated as (509*2·19 + 347*2·03 + 714*1·74)/1570 = 1·95; Differences in 
predicted values may deviate slightly from marginal effects presented in table 2 due to the non-linearity of the models.  *Predictions are based 
on models 1a (Zambia) and 2a (South Africa), and generated at sample mean values of all other covariates; @Predictions are based on models 1b 
(Zambia) and 2b (South Africa), and generated at sample mean values of all other covariates.  
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